Cargando…

Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy

Latanoprostene bunod (LBN) 0.024%, a modified prostaglandin analog, was approved on November 2, 2017, for the reduction of IOP in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). LBN works by combining the IOP-lowering effects of the prostaglandin analogs (through the uveosclera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Addis, Victoria M, Miller-Ellis, Eydie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304237/ https://www.ncbi.nlm.nih.gov/pubmed/30587912 http://dx.doi.org/10.2147/OPTH.S156038

Ejemplares similares

Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018)

Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018)

Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open‐angle glaucoma and ocular hypertension
por: Fingeret, Murray, et al.
Publicado: (2019)

Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis
por: Lo, Tzu-Chen, et al.
Publicado: (2022)

Retrospective Chart Review on Real-World Use of Latanoprostene Bunod 0.024% in Treatment-Naïve Patients with Open-Angle Glaucoma
por: Okeke, Constance O., et al.
Publicado: (2020)

Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
por: Kawase, Kazuhide, et al.
Publicado: (2016)

Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects
por: Araie, Makoto, et al.
Publicado: (2015)

Critical evaluation of latanoprostene bunod in the treatment of glaucoma
por: Garcia, Giancarlo A, et al.
Publicado: (2016)

Use of Latanoprostene Bunod as Adjunctive Glaucoma Therapy in Refractory Glaucoma
por: Zhou, Benjamin, et al.
Publicado: (2022)

Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma
por: Wang, Yulong, et al.
Publicado: (2020)

A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study
por: Weinreb, Robert N, et al.
Publicado: (2015)

Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
por: Harasymowycz, Paul, et al.
Publicado: (2022)

The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies
por: Cavet, Megan E., et al.
Publicado: (2018)

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
por: Malhotra, Ranjan P, et al.
Publicado: (2019)

An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy
por: Fung, Derrick S, et al.
Publicado: (2014)

Association of primary open-angle glaucoma with mitochondrial variants and haplogroups common in African Americans
por: Collins, David W., et al.
Publicado: (2016)

Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
por: Singh, Inder P., et al.
Publicado: (2020)

Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review
por: Russo, Andrea, et al.
Publicado: (2008)

Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date
por: Dasso, Lily, et al.
Publicado: (2018)

Safety of Fixed-Combination Bimatoprost 0.03%/Timolol 0.5% Ophthalmic Solution at 6 Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension
por: Sun, Xinghuai, et al.
Publicado: (2022)

Cost and yield considerations when expanding recruitment for genetic studies: the primary open-angle African American glaucoma genetics study
por: Salowe, Rebecca, et al.
Publicado: (2017)

Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model
por: Meier, Edward J, et al.
Publicado: (2018)

Risk factors for structural and functional progression of primary open-angle glaucoma in an African ancestry cohort
por: Salowe, Rebecca J, et al.
Publicado: (2023)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
por: Rhee, Douglas J, et al.
Publicado: (2008)

The MT-CO1 V83I Polymorphism is a Risk Factor for Primary Open-Angle Glaucoma in African American Men
por: Collins, David W., et al.
Publicado: (2018)

Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
por: Araie, Makoto, et al.
Publicado: (2021)

Mitochondrial Sequence Variation in African-American Primary Open-Angle Glaucoma Patients
por: Collins, David W., et al.
Publicado: (2013)

In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
por: Sheppard, John D., et al.
Publicado: (2018)

Primary Open-Angle African American Glaucoma Genetics (POAAGG) Study: gender and risk of POAG in African Americans
por: Khachatryan, Naira, et al.
Publicado: (2019)

Primary Open-Angle Glaucoma in Individuals of African Descent: A Review of Risk Factors
por: Salowe, Rebecca, et al.
Publicado: (2015)

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial
por: Day, Douglas G, et al.
Publicado: (2013)

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial
por: Goldberg, Ivan, et al.
Publicado: (2014)

EHMTI-0024. The typical duration of migraine aura: a prospective diary-based study
por: Viana, M, et al.
Publicado: (2014)

Letrozole in the neoadjuvant setting: the P024 trial
por: Ellis, Matthew J., et al.
Publicado: (2007)

Letrozole in the neoadjuvant setting the P024 trial
por: Ellis, Matthew J., et al.
Publicado: (2007)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
por: Tsumura, Toyoaki, et al.
Publicado: (2012)

Glaucoma awareness among people attending ophthalmic outreach services in Southwestern Ethiopia
por: Tenkir, Addis, et al.
Publicado: (2010)

Comparison of ophthalmic artery blood flow between open-angle glaucoma and nonglaucomatous eyes of Indian patients
por: Mathur, Vijay, et al.
Publicado: (2020)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
Publicado: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1n5giqevg110i8d32msfmpcpft